Format
Sort by

Send to

Choose Destination

Search results

Items: 14

1.

Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study.

Gray GE, Moodie Z, Metch B, Gilbert PB, Bekker LG, Churchyard G, Nchabeleng M, Mlisana K, Laher F, Roux S, Mngadi K, Innes C, Mathebula M, Allen M, McElrath MJ, Robertson M, Kublin J, Corey L; HVTN 503/Phambili study team.

Lancet Infect Dis. 2014 May;14(5):388-96. doi: 10.1016/S1473-3099(14)70020-9. Epub 2014 Feb 20.

2.

Does participation in an HIV vaccine efficacy trial affect risk behaviour in South Africa?

Gray GE, Metch B, Churchyard G, Mlisana K, Nchabeleng M, Allen M, Moodie Z, Kublin J, Bekker LG; HVTN 503 team.

Vaccine. 2013 Apr 12;31(16):2089-96. doi: 10.1016/j.vaccine.2013.01.031. Epub 2013 Jan 29.

3.

Long-term effects of intermittent IL-2 in HIV infection: extended follow-up of the INSIGHT STALWART Study.

Markowitz N, Lopardo G, Wentworth D, Gey D, Babiker A, Fox L, Tavel J; STALWART Study Group.

PLoS One. 2012;7(10):e47506. doi: 10.1371/journal.pone.0047506. Epub 2012 Oct 17.

4.

Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study.

Gray GE, Allen M, Moodie Z, Churchyard G, Bekker LG, Nchabeleng M, Mlisana K, Metch B, de Bruyn G, Latka MH, Roux S, Mathebula M, Naicker N, Ducar C, Carter DK, Puren A, Eaton N, McElrath MJ, Robertson M, Corey L, Kublin JG; HVTN 503/Phambili study team.

Lancet Infect Dis. 2011 Jul;11(7):507-15. doi: 10.1016/S1473-3099(11)70098-6. Epub 2011 May 11. Erratum in: Lancet Infect Dis. 2011 Jul;11(7):495.

5.

Predictors of bacterial pneumonia in Evaluation of Subcutaneous Interleukin-2 in a Randomized International Trial (ESPRIT).

Pett SL, Carey C, Lin E, Wentworth D, Lazovski J, MirĂ³ JM, Gordin F, Angus B, Rodriguez-Barradas M, Rubio R, Tambussi G, Cooper DA, Emery S; INSIGHT-ESPRIT Study Group.

HIV Med. 2011 Apr;12(4):219-27. doi: 10.1111/j.1468-1293.2010.00875.x. Epub 2010 Aug 31.

6.

Effects of intermittent IL-2 alone or with peri-cycle antiretroviral therapy in early HIV infection: the STALWART study.

Tavel JA; INSIGHT STALWART Study Group, Babiker A, Fox L, Gey D, Lopardo G, Markowitz N, Paton N, Wentworth D, Wyman N.

PLoS One. 2010 Feb 23;5(2):e9334. doi: 10.1371/journal.pone.0009334.

7.

Peritonitis prevention in continuous ambulatory peritoneal dialysis.

Luzar MA.

Nephrologie. 1992;13(4):171-7. Review.

PMID:
1407258
8.
9.

Staphylococcus aureus nasal carriage and infection in patients on continuous ambulatory peritoneal dialysis.

Luzar MA, Coles GA, Faller B, Slingeneyer A, Dah GD, Briat C, Wone C, Knefati Y, Kessler M, Peluso F.

N Engl J Med. 1990 Feb 22;322(8):505-9.

10.

Exit-site care and exit-site infection in continuous ambulatory peritoneal dialysis (CAPD): results of a randomized multicenter trial.

Luzar MA, Brown CB, Balf D, Hill L, Issad B, Monnier B, Moulart J, Sabatier JC, Wauquier JP, Peluso F.

Perit Dial Int. 1990;10(1):25-9.

11.

Exit-site infection in CAPD: a review.

Luzar MA.

Contrib Nephrol. 1990;85:57-66. Review. No abstract available.

PMID:
2078940
12.
14.
Items per page

Supplemental Content

Loading ...
Write to the Help Desk